126 results
The primary objective is to assess whether RDN by other devices than Medtronic added to usual care compared to usual care alone reduces BP in subjects, classified as non-responders on renal denervation, six months after RDN.
The objective of this study is to achieve better adherence to fluid restriction by providing insight to patient*s drinking behavior, by using the MySleeve device (MS).
To assess safety and tolerability of EA-230 in patients undergoing cardiac surgery with cardiopulmonary bypass.To assess the anti-inflammatory effects of EA-230 in patients with systemic inflammation following cardiac surgery. To assess the effects…
To establish the relationship between the use of deep neuromuscular blockade (NMB) during laparoscopic donor nephrectomy (LDN) -with standard pressure pneumoperitoneum- and the early quality of recovery.
The present study is designed to verify the hypothesis that a strategy based on a goal-directed perfusion, aimed to avoid a nadir DO2 below the critical threshold, is effective in limiting the postoperative AKI rate.
The primary objective is to evaluate the efficacy of avacopan compared to placebo based on histologic changes in kidney biopsies taken before and during treatment.The secondary objectives of this study include evaluation of:1. The safety of avacopan…
To study the potential of alkaline phosphatase to protect against ischemia-reperfusion injury in living donor kidney transplantation.
In this study we will investigate how safe the new compound R2R01 is and how well it is tolerated when it is used by healthy participants.We also investigate how quickly and to what extent R2R01 is absorbed and eliminated from the body. In addition…
To study the potential renoprotective effects of supplementation of alkaline phosphatase in hospitalized patients with AKI
To study the effects of FCM on exercise tolerance, haematinic parameters, quality of life, cardiac function, muscle function, bone and mineral parameters, microbiota, the immune system, the incidence of infections, allograft failure and mortality in…
This consortium aims to determine the best possible dialysis treatment by comparing high-dose HDF versus conventional high-flux HD treatment by carrying out a prospective randomised controlled clinical trial addressing clinical endpoints, quality of…
· To evaluate the effect of zibotentan anddapagliflozin in combination and alone versusplacebo on UACR.
This study has been transitioned to CTIS with ID 2024-510620-39-00 check the CTIS register for the current data. To compare belzutifan+lenvatinib to cabozantinib with respect to PFS per Response Criteria in Solid Tumors (RECIST) 1.1 as assessedby…
This study has been transitioned to CTIS with ID 2023-506359-68-00 check the CTIS register for the current data. This study investigates the safety and efficacy of the new drug anifrolumab in patients with Lupus Nephritis. The effect of anifrolumab…
This study has been transitioned to CTIS with ID 2024-515480-66-01 check the CTIS register for the current data. To attenuate the impact and duration of delayed graft funtion by dampening schemia reperfusion injury
The DAPARHT trial is designed to assess effect of the SGLT2 inhibitor dapagliflozin to prevent deteriorating renal function in heart transplant recipients. Secondary objectives are to assess the impact of treatment on: i) weight, ii) glucose…
This study has been transitioned to CTIS with ID 2023-506637-30-00 check the CTIS register for the current data. The main objective of this study is to determine whether lowering estrogen and progesterone levels with leuprorelin decreases liver…
The aim is to see whether intradialytic parenteral nutrition is an efective treatment against the loss of muscle mass
The primary objective is to determine the effect of nutritional preconditioning by fasting with a lowdose laxative on the severity of postoperative fatigue at 4 weeks after donor nephrectomy in adult patients.
This study has been transitioned to CTIS with ID 2022-502123-21-00 check the CTIS register for the current data. To compare the 120 mg once daily (QD) dose and 200 mg QD dose of MK*6482with respect to objective response rate (ORR) based on Response…